- Home
- KRMD vs PBYI Comparison
KRMD vs PBYI Comparison
Compare KRMD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | PBYI |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KRMD | PBYI |
|---|---|---|
| Price | $5.76 | $5.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.83 | ★ $7.00 |
| AVG Volume (30 Days) | 198.2K | ★ 402.3K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $39,070,637.00 | ★ $211,995,000.00 |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | ★ N/A | $7.87 |
| Revenue Growth | ★ 22.12 | N/A |
| 52 Week Low | $1.86 | $2.58 |
| 52 Week High | $6.11 | $6.12 |
Technical Indicators
Market Signals| Indicator | KRMD | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 69.43 | 67.11 |
| Support Level | $5.52 | $4.84 |
| Resistance Level | $6.11 | $5.11 |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 76.92 | 99.01 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.